Charles B. Klein
Chuck is the litigation office head in Washington, D.C., serves on the firm’s Executive Committee, is the former co-chair of the firm’s Intellectual Property Practice, and is the former chair of the firm’s Commercial Litigation Practice. He is a first-chair trial lawyer who litigates significant patent, antitrust, and commercial disputes. Managing Intellectual Property recently recognized him as an “IP Star,” and IAM described him as a “talisman for major pharmaceutical and biotechnology businesses” who is “no stranger to billion-dollar cases.” Six of Chuck’s first-chair victories (including three trial wins) have been mentioned in the “Litigator of the Week” column published by The American Lawyer.
Key Matters
Serving as lead trial and appellate counsel, Chuck obtained a trial judgment, affirmed on appeal, of noninfringement related to a stress-test agent. Serving as lead trial and appellate counsel, he obtained a trial judgment, affirmed on appeal, invalidating six patents related to a drug used to treat very high triglyceride levels. Serving as lead trial and appellate counsel, he obtained a trial judgment, affirmed on appeal, invalidating four patents related to a multiple sclerosis drug. Also serving as lead trial and appellate counsel, he convinced the Federal and D.C. Circuits to deny requests for injunctive relief related to a drug that treats gout. Serving as lead trial counsel, he obtained a trial judgment of non-infringement and invalidity regarding an insomnia drug. He obtained the first injunction under the Hatch-Waxman counterclaim provision—a significant ruling for the generic-drug industry that the Supreme Court ultimately upheld in a 9-0 decision. He also obtained a defense jury verdict in a US$1.7B pharmaceutical antitrust case identified by The Daily Journal as one of the “Top Verdicts of 2011.”
A biotechnology and pharmaceutical ace who continues to achieve excellent results...
IAM Patent 1000